$NBIX News

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82

Neurocrine Biosciences To Present Multiple New Analyses Of Key Clinical And Patient-Reported Outcomes Up To Two Years Of Treatment With CRENESSITY In Populations With Classic Congenital Adrenal Hyperplasia, At ENDO 2026

Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Goldman Sachs Reinstates Buy on Neurocrine Biosciences, Announces $213 Price Target

Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $183

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setup

Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform

Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential

Bernstein Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $221

Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) Narrative

A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention

Neurocrine Biosciences Hits New Highs On Earnings Surge

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New Data From Clinician Survey Highlighting Functional Impact Experienced By Patients With Mild TD Severity And Impact Of Treatment With INGREZZA Capsules In Real-World Setting